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There were three (5.4%) groin access site complications. There was one death in the first 
30 days of follow-up. This El-year-old man was readmitted with pneumonia on day 13, 
developed ARDS and died on day 26. At 30 days there ware no new neurologic events, 
and the deficits of the two patients with minor strokes post-procedure had resolved. 
Conclusion: Elderly patients were excluded from the NASCET trial due to a high risk of 
complications. Other groups have reported event rates of 19.2% in this age group for 
CAS. Our prospective database shows that CAS can be safely performed in patients 
over 60 years old and represents an attractive alternative to carobd endarterectomy. 
1129-176 Three-Year Clinical and Quantitative Angiographic 
Follow-Up After Carotid Artery Stenting 
Keita Odashira Hiroyoshi Yokoi, Katsumi Inoue, Masashi Iwabuchi, Takeshi Kimura, 
Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu. Japan 
Background: Carotid artery stenting (CAS) has evolved as a potential alternative to 
carotid endarlerectomy. However there was little angiographic follow-up data for patients 
receiving stems at extracranial carotid arteries. The purpose of this study was to assess 
the long-term safety and efficacy of CAS. Methods: Out of 31 patients with 36 lesions 
undergoing 6 months follow-up angiography, l-2 years follow-up angicgraphy was avail- 
able in 17 patients with 24 lesions and 3-4 years follow-up angiography was available in 
6 patients with 10 lesions. Quantitative angiographic analysis was performed. Minimal 
luminal diameter(MLD), interpolated referense diameter and % diameter stenosis were 
measured. Stem sites were divided into 10 segments. At each segments, minimal diame- 
ter and mean diameter were measured. External carotid artery patency were examined 
at bifurcation lesions which were covered with stents. Results: At stenotic segments 
greater than 50% before CAS, neointimal hyperplasia became greater than other seg- 
ments at 6 months. Follow-up angiography of 19 lesions at 6 months and 1-2 years 
revealed a decrease in MLD from 4.41*0.55mm immediately after stent implantation to 
3.45+0.39mm at 6 months. but no further decrease in diameter after 6 months (in 
patients with paired angiograms, 3.4520.39mm at 6 months and 3.76+0.3mm at 112 
“ears: P=O.O15). Luminal diameter stabilization was observed at 3-4 veals (in oatients 
I  .  
with paired angiograms, 3.65*0.76mm at 6 months and 4.OOkO.53 mm at 3-4 years; 
P=O.O85). At bifurcation lesions covered by stents, external carotid artery were all patent 
at follow-up angiography. There were no neurologic events associated stented sites dur- 
ing follow-up period. Conclusions: Anglographic and clinlcal outcomes up to 3 years after 
CAS were favorable, with a very low restenotic rate. Stabilization of neointimal hyperpla- 
spa appears to occur after 6 months. 
1129-177 Factor V Leiden Mutation Is Associated With Increased 
Risk for Periprocedural Neurological Deficits in Carotid 
Stenting 
Sabine Steiner, Andrea Bartok, Florian Frommelt, Erich Minx, Christoph W. Kopp, 
University of Vienna, Vienna, Austria 
Background: Factor V Leaden (factor V Arg506Gln). the genetic defect underlying resis- 
tance to activated protein C, is the most important hereditary cause of venous throm- 
boembolism. However, the potential role in arterial thrombosis and disease is still 
controversial. We questioned if patients heterozygous for the mutation are at increased 
risk for periprocedural neurological deficits (PND) during carotid stenting (CS) due to 
impaired control of thrombogenesis. 
Methods: APC resistance (APC-R) ratio was prospectively quantitated in a consecutive 
series of 137 patients who underwent CS for asymptomatic (n=l06) or symptomatic 
(n=31) high-degree (>90%) cervical internal carotid arteiy stenosis. All patients with 
reduced APC-R ware genotyped for factor V Leiden mutation. Occurence of neurological 
deficit within 46 hours after the procedure was recorded and logistic regression analysis 
performed to test the infbence of demographic and clinical factors as well as factor V 
Leiden on PND. 
Results: Patients suffering PND (n=lZ; 6.6%) were similar with respect to cardiovascular 
risk profile compared to total population.(see table) However, in five out of six patients 
who were heterozygous for factor V Leiden’mutation. neurological ischemic complica- 
tions occured with high statistical significance in uni- and multivariate analy- 
sis.(pcO.OOl)Conclusion: Factor V Leaden mutation was identified as an independent risk 
factor for periintelventional neurological deficits in CS. 






Symptomatic Carotid Stenosis.N(%) 
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PND Patients P 
N=l2 
71.0+7.7 n.s. 
8 (67%) “.S. 
4 (33%) n.s. 
24.6+3.2 n.s. 
5 (42%) “.s. 
4 (33%) n.s. 
5 (42%) n.s. 
3 (25%) n.s. 
10 (63%) “.s. 
6 (67%) n.s. 
2 (17%) “.S. 
5 (42%) <O.OOl 
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1129-197 Carotid Stenting With Intravenous Abciximab Is a Safe 
and Efficacious Strategy Compared With Carotid 
Endarterectomy 
Fernando Boccalandro, Edward Baptista. Andreas Muench. Catherine Carter, Morgan 
Campbell, Richard W. Smalling. University of Texas Houston Medical School, Houston, 
TX 
Beckground:The histopathologic analysis of embolized debris collected in distal protec- 
tion devices during carobd artery stenting (CAS) has shown predominantly thrombotic 
material, foam cells and cholesterol emboli. The use of Abciximab a potent platelet glyco- 
protein Ilb/llla receptor inhibitor, has shown to reduce the risk of ischemic events associ- 
ated with coronary interventions and can potentially inhibit the thrombatic component of 
distal emboli described during CAS. The objective of this study is to evaluate the safety 
and effectiveness of the use of Abciximab during carotid stenting compared with carotid 
endarterectomy (CAE). Methods:Abciximab was intravenously administered as a single 
bolus (0.25 mg/kg) and then via infusion (10 mglmin) for 12 hours following CAS in 54 
patients (31 males, 65+12 Yr). In-hospital and 30-day outcomes was compared with 55 
patients undergoing elective CAE (27 males, 76+10). In addition, bleeding complications 
were also recorded. Bleeding complications were classified as major (hemoglobin 
decrease ~5 gidL) or minor (hemoglobin decrease < 5g/dL).Results: NO significant dif- 
ferences wars observed between the demographic characteristics of both groups. 







Carotid Stenting Carotid Endarterectomy P Value 
2 (3.7%) 3 (5.4%) 0.671 
1(1.9%) 2(3.6%) 0.561 
2(3.7%) 1(1.6%) 0.549 
0 1(1.6%) 0.321 
TIA 1(1.9%) 1(1.6%) 0.975 
Stroke 0 1(1.6%) 0.321 
Death 0 0 1 
Myocardial Infarction 1(1.9%) 0 0.306 
Major Bleeding 4(7.4%) 3(5.4%) 0.670 
Minor Bleeding 4(7.4%) 2(3.6%) 0.391 
Hospital Stay (Days) 1.4io.7 2.5+1.5 < 0.01 
Conclusion: 
Outcomes of carotid artery stenting plus adjuvant Abciximab are comparable with elec- 
tive CAE, although CAE was associated with a shorter hospital stay. The use of Abcix- 
imab during carotid stenting was not associated with increased risk of bleeding when 
compared with CAE. 
1129-196 Comparison of the Safety and Efficacy of the Use of 
Emboli Protection Device Versus Glycoprotein llblllla 
Inhibitor During Carotid Stenting 
Albert W. Ghan, Deepak L. Bhatt, Christopher T. Bajzer, Eric J. Topol, Jay S. Yadav, 
Ochsner Clinic Foundation, New Orleans, LA, The Cleveland Clinic Foundation, 
Cleveland, OH 
Background: Distal embolizabon constitutes the main potential risk of carotid stenting, 
and techniques to minimize this risk are evolving. Platelet glycoprotein llblllla inhibitors 
(GPI) have been used to reduce the consequences of distal embolization. Recently, 
emboli-protection devices (EPD) have become available and we compared the outcomes 
of these two strategies. 
Methods: Between 0711996 and 03/2002, GPI was used during elective or urgent percu- 
taneous carotid intervention until lOI2000, and EPD was introduced since 07l2000. Fol- 
low-up data ware prospectively collected at 30 days after procedures. Patients who 
received both GPI and EPD were excluded. 
Results: A total of 305 consecutive patients underwent the procedure (199 patients 
received adjunctive GPI [91% abciximab] and 106 patients had EPD [65% filter design, 
15% occlusive balloon]). Compared with GPI, EPD was associated with a trend of lower 
incidence of composite endpoints of neurological death, non-fatal stroke, and intracranial 
hemorrhage, and a significantly lower mcldence of major bleeding (Table). Overall, the 
composite endpoints of neurological death, non-fatal stroke, major bleeding, including 
intracranial hemorrhage, was significantly less frequent with EPD than with GPI. 
Conclusions: EPD may provide an overall safer and more effective means of neuropro- 
tection during carotid stenting as compared with GPI. 
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Clinical Events within 30 days 
Neurological Death (“‘) 
Non-fatal stroke (“‘%) 
Intracranial Hemorrhage (%) 
Neurological Death, Non-fatal Stroke, or Intracranial 
Hemorrhage (%) 
Major Bleeding (%) 
Neurological Death, non-fatal Stroke, Intracranial 
Hemorrhage, or Major Bleeding (%) 
EPD GPI P 
(N=l06) (N=l99) 
0 1.5 0. 
20 
0 1.0 0. 
55 
0 2.0 0. 
14 
0 2.5 0. 
10 
0 4.6 0. 
03 
0 5.1 0. 
02 
1129-199 Predictors of Adverse Events Complicating Carotid 
Artery Stenting in the Era of Distal Protection Devices 
Ramtin Aaah. Leslie Cho, Jacob Schneider, Albert W. Ghan. Marco Roffi, Christopher T. 
Bajzer, Jay S. Yadav, The Cleveland Clinic Foundation, Cleveland, OH 
Introduction: Despite the rapid acceptance of carotid stenting(CS) as an alternative to 
endarterectomy. little is known about clinical and angiographic predictors of poor out- 
come with CS in the current era. Methods: Using the data from our registry of 351 con- 
secutive patients who underwent CS between 1998 and 2001, we looked at 40 different 
clinical and angiographic variables to assess potential predictors of adverse events(AE). 
Majority of the patients in our registry had distal emboli protection devices used in con- 
junction with CS. Adverse events was defined as a combined endpoint of myccardial inf- 
arction, stroke, and death. Using multi-variate analysis, the predictors of AE peri- 
procedurally and at 6 months are shown. Resultsz The most significant predictors of 
peri-procedural AE were histoly of stroke, transient ischemic attack(TlA) and need for 
open heart surgery(pre-OHS). Also patients with COPD were at higher risk of events in 
our analysis. We found no association between patient’s age, lesion characteristics (cal- 
cification, morphology or diameter), contra-lateral carotid stenosis/occlusion and AE. At 6 
months, the predictors of poor outcome were low cardiac ejection fraction and diabetes. 
Conclusions: In the current era, patients who undergo CS with symptomatic lesions or 
are pm-OHS have higher peri-procedural AE; beyond the procedural period the tradi- 
tional risk factor for cardiovascular events, diabetes and low ejection fraction become 
mrxe important predictor of events. 
Time-point Predictor P-value 
Peri-procedural Histoly of Stroke 0.0041 
History of TIA 0.049 
Pm-OHS 0.010 
6.months 
History of COPD 0.030 
Diabetes 0.048 
Baseline EF<30% 0.016 
1129-200 Chronic VisceraVMesenteric Ischemia: Role of 
Percutaneous Angioplasty and Stenting in Cellac and 
Mesenteric Artery Disease 
David E. Allie, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. 
Khan, Muhammad A. Khan, Peter S. Fail, Chris J. Hebert, Adam A. Allie, Craig M. 
Walker, Cardiovascular Institute of the South, Lafayette, LA, Columbia Medical Canter of 
Southwest Louisiana, Lafayette, LA 
Backaround: Surgical treatment for chronic mesenteric ischemia (CMI) is effective but 
technically demanding with operative mortality ranges from 3-14.7% (mean=7.5%) and 
morbidity ranges from E-44.7% (mean=28%). Percutaneolis transluminal angioplasty 
(PTA) alone for CMI is reported but has excessive recurrence rates (12.60%; 
mean=26%). Sparse data exists regarding indications, safety, feasibility, and durability of 
PTAlstenting for celiac and mesenteric artery disease. 
Methods: Between January 1998July 2002, 68 visceral artery stenosis [42 superior 
mesenteric (SMA) and 26 celiac artery (CA)] underwent PTAIstenting in 45 patients with 
CMI. A multivariable retrospective chart review was performed. Abdominal pain and 
weight loss wsre present in 41/45 (91%) and 39/45 (87%) respectively. An 8-French 
transfemoral approach was used in 30/42 (71%) SMA and 21/26 (80%) CA. A transbra- 
chial approach was required in 12/42 (29%) SMA and 5/20 (20%) CA. All patients 
received balloon expandable stems. 30168 (44%) vessels had 6 month duplex ultrasound 
(DU) and 25/88 (36%) angiography at median follow up of 23 months (range 7-54 
months). 
Results: Procedural success 67168 (98.5%) with 6 requiring a change from femoral to 
brachial access. No bowel infarction, stent thrombosis, or procedural deaths occurred. 
Pain relief improved in 38/42 (92%) and weight gain in 35139 (90%). 3/55 (5.4%) avail- 
able for objective follow-up developed restenosis (DU 2130 (6.6%) and angiography l/25 
(5%)] requiring repeat PTA/stenting for 100% primary assisted mid-term clinical succsss. 
There were no major complications requiring surgery and 2 minor access site hemato- 
mas (< 2 cm). 30.day mortality 0%. No late bowel related deaths. The l-year and P-year 
symptom free survival rates were 97.5% and 89.5% respectively. 
Conclusion: PTA/stenting for SMA and CA disease is a safe and effective treatment 
option for CMI offering excellent immediate and mid-term clinical succsss. 
1129-201 Bivalirudin as Sole Anticoagulant in Peripheral Vascular 
Disease: A Safety and Feasible Alternative in Renal and 
iliac Interventions 
David E. Allie, Mitchell D. Lirtzman, Charles H. Wyatt, V. Antoine Keller, Mohamed H. 
Khan, Muhammad A. Khan, Peter S. Fail, Chris J. Hebert, Adam A. Allie, Craig M. 
Walker, Cardiovascular Institute of the South, Lafayette, LA, Columbia Medical Center of 
Southwest Louisiana. Lafayette, LA 
Backaround: Many heparin limitations are Overcome by the direct thrombin inhibitor 
bivalirudin (Angiomax, The Medicines Company, Parsippany, NJ). Bivalirudin has shown 
a reduced incidence of ischemic and bleeding complications post percutaneous coronary 
interventions. The pharmacokinetic profile of bivalirudin appears well suited for percuta- 
neous peripheral intervention (PPf) yet few data exist regarding safety and feasibility in 
this setting. 
Methods: 180 renal and 75iliac PPl’s ware performed (May 2001-June 2002) with biva- 
lirudin as anticoagulation and compared to a historical heparin control (HC). Angiomax 
dose: 0.75 mglkg bolus with 1.75 mglkglhr infusion for procedural duration. Variables: 
Sheath removal time (SRT), access complication (AC), time to ambulate (TA), and length 
of stay (LOS). Follow up: 6 month renal and iliac duplex ultrasound. 
Rssultg No thrombotic events, intracranial bleeding, or major surgical complications 
occurred in bivalirudin group (BG). SRT, TA and LOS were reduced compared to HC 
(Table). 7/180 (3.8%) renal and 31’75 (4%) iliac required repeat PPI. 
Conclusion: Bivalirudin is a safe and feasible alternative anticoagulant in renal and iliac 






PPI success, ” 180 (100) 
(%) 
AC (Majorl), n 2(1.1) 
(%) 
AC (MinoR), 5(2.7) 
ll(%) 
SRT ~60 min, n 152 (84) 
(%) 
SRT >60 min, n 28 (16) 
(“@ 
LOS ~24 hrs, n 154(85.5) 
(%) 
LOS >24 hrs, ” 26(14.5) 
(%) 
TA <8 hrs, ” (“‘%) 136(75.5) 











P- Bc. HC Iliac 
VEdW Iliac n=75 
n=75 
0.3173 75 (100) 74 (98.6) 
0.1532 2(2.5) 3 (4) 
0.3974 3(4) 5 (6.6) 
<O.OOO 36 (48) 21 (28) 
1 
~0.000 39 (52) 54 (72) 
1 
0.002 42(56) 32 (43) 
0.002 33(44) 43(57) 
0.0005 31(41) 19 (25) 





















l=“Major’ = any surgery, > 5 cm hematoma, or > 2u transfusion 
P=‘Minor’ = all other non-intracranial or retroperitoneal bleeding 
1129-202 Is Bivalirudin a Safe Alternative to Heparin During 
Carotid Stenting? A Case Matched Study 
Yuliva G. Adamvan, Gishel New, Sriram lyer, Thosaphol Limpijankit, Christina Brennan, 
Milena G. Adamian, Roxana Mehran, lzat Hjazi. Zoran Lasic, Sheriff Ibrahim, Jiri J. Vitek, 
Gary S. Roubin, Cardiovascular Research Foundation, New York, NY, Lenox Hill Heart 
and Vascular Institute, New York, NY 
Backaround: Previous studies have shown safetv and feasibilitv of the direct thrombin 
inhibitor Bivalirudin (B) during percutaneous coronary interventions. However, the safety 
txofile of this aaent as an alternative to unfractionated Heoann (UFH) durina carotid 
stenting (CS) is not known. 
_ 
Methods: From December 2001 to September 2002,59 consecutive pts (mean age = 72 
+ 9 yrs, 80.4% male) underwent CS with B and compared to 83 case matched controls 
receiving UFH during the same timeframe. B was administered in bolus dose of 0.75mgl 
kg, followed by drip (1.75 mg/kg/hr) throughout the procedure. 5,000 units of UFH were 
administered prior to the procedure in the UFH group. No GP Ilb/llla inhibitors were 
used. Neurological events, bleeding and vascular complications were recorded and adju- 
dicated by an independent committee. 
Results: Closure devices were used more often in B group than in UFH group (76.3% 
vs. 28.9% respectively, p< 0.0001). In-Hospital neurologic and vascular complications 
are shown in table. 
